Showing results (141-150 of 184) with videos related to
Sort By:
Pageof 19
Hepatology (Baltimore, Md.)|February 15, 2012
Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic responseSusanna Naggie, Anu Osinusi, Antonios Katsounas, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 9, 2008
Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis CDavid R Nelson, Vinod Rustgi, Vijayan Balan, et al.Journal of Clinical Gastroenterology|May 16, 2014
Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicitySteven L Flamm, Andrew J Muir, Michael W Fried, et al.Hepatology Communications|October 26, 2022
Factors associated with cardiovascular events after simultaneous liver-kidney transplant from the US Multicenter Simultaneous Liver-Kidney Transplant ConsortiumJennifer Jo, Gonzalo Crespo, Dyanna Gregory, et al.Hepatology (Baltimore, Md.)|November 3, 2011
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment responseAndrew J Muir, Fred F Poordad, John G McHutchison, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 25, 2020
Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing CholangitisPalak J Trivedi, Andrew J Muir, Cynthia Levy, et al.Hepatology (Baltimore, Md.)|August 4, 2020
A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing CholangitisYevgeniy Gindin, Chuhan Chung, Zhaoshi Jiang, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 5, 2020
Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus InfectionEli Zuckerman, Julio A Gutierrez, Douglas E Dylla, et al.Gastroenterology|July 6, 2010
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1Stefan Zeuzem, Mark S Sulkowski, Eric J Lawitz, et al.Hepatology (Baltimore, Md.)|January 29, 2011
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVRAlexander J Thompson, Rosanna Santoro, Valeria Piazzolla, et al.Pageof 19